[SHINSA]Points to Consider for the Development of Companion Diagnostics Developed in Parallel with Anti-cancer Drugs(Early Consideration) and Quality-Related Considerations for Human Cell-Derived Extracellular Vesicle (EV) Products at the Time of Initial Clinical Trial Notification (Early Consideration) posted.
Imported from official source
This version
- Version
- 3 of 5
- Recorded
- October 19, 2026 00:32
- Change
- Imported change
- Content hash
5419ee49d7f5c3184f889c670ea25446- All versions
- Revision history